Evidence map›Paper›PMID 42009378›Full record

ArticleBMJ open2026

Linezolid in addition to standard antibiotic treatment for

Natalie Rose, Nadine S Bernasconi, Michaela Schumacher, Laura Werlen, David Büchel, Maja Weisser, Severin B Vogt, Elisabeth Wehrle-Wieland, Anna Conen, Maria C Thurnheer and 13 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06958835 (Combination Antibiotic Treatment With Linezolid for Staphylococcus Aureus Bacteraemia), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06958835 narecruitingnot on this map

Combination Antibiotic Treatment With Linezolid for Staphylococcus Aureus Bacteraemia: a Randomised Controlled Trial

TypeinterventionalSponsorUniversity Hospital, Basel, SwitzerlandRan2025 to 2028Enrolled606ConditionsStaphylococcus Aureus Bloodstream Infections (BSI, Bacteremia)ArmsLinezolid 600 mg, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Natalie RoseDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-5102-4385
Nadine S BernasconiDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.
Michaela SchumacherDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.
Laura WerlenDepartment of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
David BüchelDepartment of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
Maja WeisserDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.
Severin B VogtDepartment of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
Elisabeth Wehrle-WielandDivision of Infectious Diseases, Claraspital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-4769-636X
Anna ConenDepartment of Infectious Diseases and Infection Prevention, Cantonal Hospital Aarau, Aarau, Switzerland.
Maria C ThurnheerDepartment of Infectious Diseases, University Hospital Inselspital and University of Bern, Bern, Switzerland.
Yonas MartinDepartment of Infectious Diseases, University Hospital Inselspital and University of Bern, Bern, Switzerland.
Michèle BirrerDepartment of General Internal Medicine / Infectious Diseases, Hôpital du Jura, Delémont, Switzerland.
Marco BongiovanniDivision of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland.ORCID http://orcid.org/0000-0003-2999-3707
Werner C AlbrichDivision of Infectious Diseases, Infection Prevention and Travel Medicine, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Urs KarrerDivision of Infectious Diseases, Department of Medicine, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Adrian SchibliDivision of Infectious Diseases and Infection Prevention, Stadtspital Zürich, Zürich, Switzerland.ORCID http://orcid.org/0009-0009-5170-0254
Stephan HarbarthInfection Control Program and World Health Organization Collaborating Centre, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.
Matthaios Papadimitriou-OlivgerisInfectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Matthias BrielCLEAR-Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-2070-5230
Barbara HasseDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Zürich, Switzerland.
Nina KhannaDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.
Richard KuehlDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.
Benjamin SpeichCLEAR-Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland benjamin.speich@usb.ch.ORCID http://orcid.org/0000-0002-3301-8085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMETHODS AND ANALYSIS: We will conduct a two-arm, parallel-group, multicentre, randomised controlled trial (Linezolid Plus Standard of Care) in 12 hospitals in Switzerland with blinded treating physicians, patients and outcome assessors. Hospitalised patients aged ≥18 years with ETHICS AND DISSEMINATION: Ethical approval was received from the Ethics committee for Northern and Central Switzerland (BASEC number 2025-00655). Eligible patients will be informed about the study by the local study team and asked for written consent if they wish to participate. For patients unable to provide informed consent, an appropriate substitute (ie, a close relative or a physician not involved in the research project) may make decisions based on the presumed wishes and the best interest of the patient. The patient's own consent will be obtained as soon as their condition permits. Results will be published in peer-reviewed journals and in laymen's terms through various channels (social media, Swiss national portal HumRes). TRIAL REGISTRATION NUMBER: NCT06958835.

Indexed as

Anti-Bacterial AgentsBacteremiaLinezolidStaphylococcal InfectionsStaphylococcus aureusDrug Therapy, CombinationFemaleHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicSwitzerlandTreatment OutcomeAnti-Bacterial AgentsLinezolidAntibioticsClinical TrialINFECTIOUS DISEASES

Identifiers

PMID42009378
PMCPMC13110666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.